Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Alzheimer's disease (AD) is the most common dementia disorder of later life. Although there might be various different triggering events in the early stages of the disease, they appear to converge on a few characteristic final pathways in the late stages, characterized by inflammation and neurodegeneration. Here, we review the hypothesis that advanced glycation end products (AGEs), which reflect carbonyl stress, an imbalance between the production of reactive carbonyl compounds and their detoxification, can serve as biomarkers for the progression of disorder. AGE modification may explain many of the neuropathological and biochemical features of AD, such as extensive protein cross-linking shown as amyloid plaques and neurofibrillary tangles, inflammation, oxidative stress and neuronal cell death. Although accumulation of AGEs is a normal feature of aging, it appears to be significantly accelerated in AD. We suggest that higher AGE concentrations in brain tissue and in cerebrospinal fluid might be able to distinguish between normal aging and AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Copper, iron and zinc in Alzheimer's disease senile plaques
Lovell, M. A., Robertson, J. D., Teesdale, W. J., Campbell, J. L., & Markesbery, W. R. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00092-6 · Cited by 2,120 · cited 1×
“Unchelated transition metals, such as copper and iron have been observed loosely bound to amyloid plaques (35).”
BackgroundActivation of microglial cells by β-amyloid protein and interferon-γ
Meda, L., Cassatella, M. A., Szendrei, G. I., Otvos, L., Baron, P., Villalba, M., Ferrari, D., & Rossi, F. (1995) · Nature · doi:10.1038/374647a0 · Cited by 1,314
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643
Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
Yan, S. D., Chen, X., Schmidt, A. M., Brett, J., Godman, G., Zou, Y. S., Scott, C. W., Caputo, C., Frappier, T., & Smith, M. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7787 · Cited by 565
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons
Mandelkow, E.-M., Thies, E., Trinczek, B., Biernat, J., & Mandelkow, E. (2004) · The Journal of Cell Biology · doi:10.1083/jcb.200401085 · Cited by 236
Reed, T. T., Pierce, W. M., Markesbery, W. R., & Butterfield, D. A. (2009) · Brain Research · doi:10.1016/j.brainres.2009.04.009 · Cited by 190
Horie, K., Miyata, T., Yasuda, T., Takeda, A., Yasuda, Y., Maeda, K., Sobue, G., & Kurokawa, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6944 · Cited by 137
Kuhla, B., Haase, C., Flach, K., Lüth, H.-J., Arendt, T., & Münch, G. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m609521200 · Cited by 119 · cited 1×
“AGE formation on proteins is irreversible and causes protease resistant cross-linking of peptides and proteins, often leading to protein deposition and amyloidosis (25, 26).”
BackgroundSelf-citationBlatnik, M., Thorpe, S. R., & Baynes, J. W. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1433.047 · Cited by 109
Substrate-specific reduction of PP2A activity exaggerates tau pathology
Deters, N., Ittner, L. M., & Götz, J. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.12.140 · Cited by 39
Cited by
Moldogazieva, N. T., Mokhosoev, I. M., Mel’nikova, T. I., Porozov, Y. B., & Terentiev, A. A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/3085756 · Cited by 493
Brain metabolic dysfunction at the core of Alzheimer's disease
de la Monte, S. M., & Tong, M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.012 · Cited by 461
Estrogens, Neuroinflammation, and Neurodegeneration
Villa, A., Vegeto, E., Poletti, A., & Maggi, A. (2016) · Endocrine Reviews · doi:10.1210/er.2016-1007 · Cited by 423
Advanced glycation end products and neurodegenerative diseases: Mechanisms and perspective
Li, J., Liu, D., Sun, L., Lu, Y., & Zhang, Z. (2012) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2012.02.018 · Cited by 319
Gut microbiota, immune development and function
Bengmark, S. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2012.09.002 · Cited by 262
Metadata
- Authors
- Rahmadi, A., Steiner, N., & Münch, G.
- Venue
- cclm
- Publisher
- Walter de Gruyter GmbH
- Published
- 2011-01-31
- Volume
- 49
- Issue
- 3
- Pages
- 385-391
- ISSN
- 1434-6621 (ISSN-L)
- 1437-4331
- OpenAlex
- W2137471813
- Cited by
- 62
- References
- 10
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. https://app.cochat.ai/papers/10.1515/cclm.2011.079
- The paper
- Rahmadi, A., Steiner, N., & Münch, G. (2011). Advanced glycation endproducts as gerontotoxins and biomarkers for carbonyl-based degenerative processes in Alzheimer's disease. cclm. https://doi.org/10.1515/cclm.2011.079
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.